Latest & greatest articles for hydrochlorothiazide

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hydrochlorothiazide or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hydrochlorothiazide and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hydrochlorothiazide

1. Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses (Full text)

Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses Roush GC, Holford TR, Guddati AK CRD summary This review and network meta-analysis concluded that chlortalidone (...) was better than hydrochlorothiazide for preventing cardiovascular events, in patients with hypertension. There were concerns about the limited search, poor reporting, and indirect analysis, but the results and conclusions are likely to be reliable. Authors' objectives To compare chlortalidone and hydrochlorothiazide for reducing the number of cardiovascular events, in patients with hypertension. Searching PubMed was searched, and Ovid was used to search for English-language publications, to July 2011

2012 DARE. PubMed abstract

2. Hydrochlorothiazide: risk of non-melanoma skin cancer, particularly in long-term use

Hydrochlorothiazide: risk of non-melanoma skin cancer, particularly in long-term use Hydrochlorothiazide: risk of non-melanoma skin cancer, particularly in long-term use - GOV.UK GOV.UK uses cookies to make the site simpler. Search Hydrochlorothiazide: risk of non-melanoma skin cancer, particularly in long-term use Advise patients taking hydrochlorothiazide-containing products of the cumulative, dose-dependent risk of non-melanoma skin cancer, particularly in long-term use, and the need (...) of hydrochlorothiazide (see of data below) inform patients taking hydrochlorothiazide-containing products of the risk of non-melanoma skin cancer, particularly in long-term use, and advise them to regularly check for and report any new or changed skin lesions or moles reconsider the use of hydrochlorothiazide in patients who have had previous skin cancer examine all suspicious moles or skin lesions (potentially including histological examination of biopsies) advise patients to limit their exposure to sunlight and UV

2018 MHRA Drug Safety Update

3. Randomised controlled trial: In individuals at intermediate risk for cardiovascular disease, treatment with rosuvastatin but not candesartan plus hydrochlorothiazide lowers cardiovascular disease event rates

Randomised controlled trial: In individuals at intermediate risk for cardiovascular disease, treatment with rosuvastatin but not candesartan plus hydrochlorothiazide lowers cardiovascular disease event rates In individuals at intermediate risk for cardiovascular disease, treatment with rosuvastatin but not candesartan plus hydrochlorothiazide lowers cardiovascular disease event rates | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising (...) In individuals at intermediate risk for cardiovascular disease, treatment with rosuvastatin but not candesartan plus hydrochlorothiazide lowers cardiovascular disease event rates Article Text Therapeutics/Prevention Randomised controlled trial In individuals at intermediate risk for cardiovascular disease, treatment with rosuvastatin but not candesartan plus hydrochlorothiazide lowers cardiovascular disease event rates Michael LeFevre Statistics from Altmetric.com Commentary on: Lonn EM , Bosch J , López

2016 Evidence-Based Medicine

4. How do hydrochlorothiazide and chlorthalidone compare for treating hypertension?

How do hydrochlorothiazide and chlorthalidone compare for treating hypertension? How do hydrochlorothiazide and chlorthalidone compare for treating hypertension? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics How do hydrochlorothiazide and chlorthalidone compare for treating hypertension? View/ Open Date 2014-04 (...) Format Metadata Abstract Q. How do hydrochlorothiazide and chlorthalidone compare for treating hypertension? A. Both medications reduce theincidence of cardiovascular events in patients with hypertension, but chlorthalidone may confer additional cardiovascular risk reduction (strength of recommendation [SOR]: B, conflicting network meta-analysis and cohort studies). (No head-to-head studies of hydrochlorothiazide [HCTZ] and chlorthalidone have been done.) Serious hypokalemia and hyponatremia can

2014 Clinical Inquiries

5. Hydrochlorothiazide

Hydrochlorothiazide Top results for hydrochlorothiazide - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 (...) or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for hydrochlorothiazide The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many

2018 Trip Latest and Greatest

6. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. (Full text)

Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. The optimal combination drug therapy for hypertension is not established, although current U.S. guidelines recommend inclusion of a diuretic. We hypothesized that treatment with the combination of an angiotensin-converting-enzyme (ACE) inhibitor and a dihydropyridine calcium-channel blocker would be more effective in reducing the rate of cardiovascular events than treatment with an ACE inhibitor plus (...) a thiazide diuretic.In a randomized, double-blind trial, we assigned 11,506 patients with hypertension who were at high risk for cardiovascular events to receive treatment with either benazepril plus amlodipine or benazepril plus hydrochlorothiazide. The primary end point was the composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, hospitalization for angina, resuscitation after sudden cardiac arrest, and coronary revascularization.The baseline characteristics

2008 NEJM Controlled trial quality: predicted high PubMed abstract

7. Enalapril, atenolol, and hydrochlorothiazide in mild to moderate hypertension. A comparative multicentre study in general practice in Norway. (Abstract)

Enalapril, atenolol, and hydrochlorothiazide in mild to moderate hypertension. A comparative multicentre study in general practice in Norway. Enalapril, atenolol, and hydrochlorothiazide were compared in a double-blind randomised parallel study in general practice. 436 patients with mild to moderate hypertension were included at 76 centres. A two-week placebo run-in period was followed by 16 weeks of monotherapy. The initial doses were: enalapril 20 mg; atenolol 50 mg; and hydrochlorothiazide (...) 25 mg. These were doubled if treatment was not effective after 4 weeks. Adverse reactions were the main reason for withdrawal from the study (9 on enalapril, 19 on atenolol, and 8 on hydrochlorothiazide). Systolic and diastolic blood pressures were significantly reduced in all three groups. The reduction in systolic blood pressure was greater on enalapril than on atenolol. Serum potassium was reduced and uric acid increased on hydrochlorothiazide. Fasting blood sugar rose on atenolol but fell

1986 Lancet Controlled trial quality: uncertain

8. Hydrochlorothiazide use and risk of non-melanoma skin cancer: A nationwide case-control study from Denmark. (Full text)

Hydrochlorothiazide use and risk of non-melanoma skin cancer: A nationwide case-control study from Denmark. Hydrochlorothiazide, one of the most frequently used diuretic and antihypertensive drugs in the United States and Western Europe, is photosensitizing and has previously been linked to lip cancer.To examine the association between hydrochlorothiazide use and the risk of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).From the Danish Cancer Registry, we identified patients (...) (cases) with nonmelanoma skin cancer (NMSC) during 2004-2012. Controls were matched 1:20 by age and sex. Cumulative hydrochlorothiazide use (in 1995-2012) was assessed from the Danish Prescription Registry. Using conditional logistic regression, we calculated odds ratios (ORs) for BCC and SCC associated with hydrochlorothiazide use.High use of hydrochlorothiazide (≥50,000 mg) was associated with ORs of 1.29 (95% confidence interval [CI], 1.23-1.35) for BCC and 3.98 (95% CI, 3.68-4.31) for SCC. We

2017 Journal of American Academy of Dermatology PubMed abstract

9. [Treatment of mild and moderate hypertension with the use of captopril alone or combined with hydrochlorothiazide. A multicenter study]. (Abstract)

[Treatment of mild and moderate hypertension with the use of captopril alone or combined with hydrochlorothiazide. A multicenter study]. The efficacy of captopril 25 mg/day as monotherapy or when necessary, in association with hydrochlorothiazide 25 mg/day, was studied during three months in 472 patients, average age 45 (17-59) years, 51% males with mild (73%) 95 less than PAD less than 104 mmHg, and moderate (27%) arterial hypertension 104 less than PAD less than 114 mmHg. Were included (...) hydrochlorothiazide 25 mg/day. After three months under treatment, 411 (87%) patients normalized their dyastolic blood pressure DBP (less than 90 mmHg), from them, 273 (57.6%) had received only captopril and the others 138 (29.4%) with the addition of hydrochlorothiazide. The drop of mean arterial pressure, MAP = 2 DBP + 1 SBP was in average, 17.3 mmHg, in the 3 patients whose blood pressure normalized with captopril alone, and in average of 18.5 mmHg in those patients requiring addition of hydrochlorothiazide

1990 Arquivos brasileiros de cardiologia

10. Efficacy and Safety of Olmesartan Associated With Chlorthalidone Versus Losartan Associated With Hydrochlorothiazide (Hyzaar®) in Essential Hypertension Control

Efficacy and Safety of Olmesartan Associated With Chlorthalidone Versus Losartan Associated With Hydrochlorothiazide (Hyzaar®) in Essential Hypertension Control Efficacy and Safety of Olmesartan Associated With Chlorthalidone Versus Benicar HCT® in Essential Hypertension Control - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study (...) Arterial Hypertension Drug: Olmesartan medoxomil 40mg + chlorthalidone 12,5mg Drug: Olmesartan medoxomil 40mg + chlorthalidone 25mg Drug: Olmesartan 40mg + Hydrochlorothiazide 12,5mg Drug: Olmesartan 40mg + Hydrochlorothiazide 25mg Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 348 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator

2015 Clinical Trials

11. Differential effects of lercanidipine/enalapril versus amlodipine/enalapril and hydrochlorothiazide/enalapril on target organ damage and sympathetic activation in non-obese essential hypertensive subjects. (Abstract)

Differential effects of lercanidipine/enalapril versus amlodipine/enalapril and hydrochlorothiazide/enalapril on target organ damage and sympathetic activation in non-obese essential hypertensive subjects. The aim of the present study was to compare the effects of the combination of lercanidipine/enalapril versus amlodipine/enalapril and hydrochlorothiazide/enalapril on blood pressure, target organ damage and sympathetic activation in patients with grade 2 essential hypertension.This was a 3 (...) month, randomized, blinded-endpoint study in essential hypertensive patients.Office and ambulatory blood pressure, arterial stiffness, urinary albumin to creatinine ratio, renal arterial resistive index, and muscle sympathetic nerve activity were evaluated at baseline, after a 2 week run-in placebo period, at 1 month and at 3 months.In total, 56 patients were assigned to lercanidipine/enalapril (n = 19), enalapril/amlodipine (n = 18) and hydrochlorothiazide/enalapril (n = 19). Each pharmacological

2016 Current medical research and opinion Controlled trial quality: uncertain

12. Efficacy and effectiveness of valsartan/amlodipine and valsartan/amlodipine/hydrochlorothiazide in hypertension: randomized-controlled versus observational studies. (Abstract)

Efficacy and effectiveness of valsartan/amlodipine and valsartan/amlodipine/hydrochlorothiazide in hypertension: randomized-controlled versus observational studies. The aim of this post-hoc analysis was to compare the results from randomized controlled trials (RCTs) and real-world evidence (RWE) studies of valsartan/amlodipine (Val/Aml) and valsartan/amlodipine/hydrochlorothiazide (Val/Aml/HCTZ) in patients with uncontrolled hypertension (>140/90 mmHg).Data was pooled from 15 RCTs (N = 5542

2017 Current medical research and opinion

13. Efficacy of Low-Dose Chlorthalidone and Hydrochlorothiazide as Assessed by 24-h Ambulatory Blood Pressure Monitoring. (Full text)

Efficacy of Low-Dose Chlorthalidone and Hydrochlorothiazide as Assessed by 24-h Ambulatory Blood Pressure Monitoring. Thiazide and thiazide-like diuretic agents are being increasingly used at lower doses. Hydrochlorothiazide (HCTZ) in the 12.5-mg dose remains the most commonly prescribed antihypertensive agent in the United States.This study compared chlorthalidone, 6.25 mg daily, with HCTZ, 12.5 mg daily, by 24-h ambulatory blood pressure (ABP) monitoring and evaluated efficacy. Because HCTZ (...) -dose HCTZ monotherapy is not an appropriate antihypertensive drug. (Comparative Evaluation of Safety and Efficacy of Hydrochlorothiazide CR with Hydrochlorothiazide and Chlorthalidone in Patients With Stage I Essential Hypertension; CTRI/2013/07/003793).Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

2016 Journal of the American College of Cardiology Controlled trial quality: uncertain PubMed abstract

14. Effect of Hibiscus sabdariffaon blood pressure and electrolyte profile of mild to moderate hypertensive Nigerians: A comparative study with hydrochlorothiazide. (Full text)

Effect of Hibiscus sabdariffaon blood pressure and electrolyte profile of mild to moderate hypertensive Nigerians: A comparative study with hydrochlorothiazide. Hibiscus sabdariffa (HS) is widely consumed in Nigeria as a refreshing beverage and also as an antihypertensive agent. Since three decades ago when its antihypertensive activities were reported in several animal experiments, its consumption has greatly increased.The aim of this study is to investigate the effect of HS consumption (...) on blood pressure (BP) and electrolytes of mild to moderate hypertensive Nigerians and compare it with that of hydrochlorothiazide (HCTZ), a diuretic widely used as first-line antihypertensive drug.Eighty newly diagnosed, but untreated mild to moderate hypertensive subjects attending Medical Out-Patients clinic of Enugu State University Teaching Hospital, Enugu, were recruited for the study. They were randomly divided into three groups: A, B and C. Those in Groups A were given placebo; those in Group B

2015 Nigerian journal of clinical practice Controlled trial quality: uncertain PubMed abstract

15. Comparison of Benazepril Plus Amlodipine or Hydrochlorothiazide in High-Risk Patients With Hypertension and Coronary Artery Disease. (Abstract)

Comparison of Benazepril Plus Amlodipine or Hydrochlorothiazide in High-Risk Patients With Hypertension and Coronary Artery Disease. Combination therapy with benazepril 40 mg and amlodipine 10 mg (B+A) has been shown to be more effective than benazepril 40 mg and hydrochlorothiazide (HCTZ) 25 mg (B+H) in reducing cardiovascular (CV) events in high-risk patients with stage 2 hypertension with similar blood pressure reductions. In the present post hoc analysis, we evaluated whether B+A is more

2013 American Journal of Cardiology Controlled trial quality: uncertain

16. A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension. (Full text)

A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension. Azilsartan medoxomil (AZL-M), an angiotensin II receptor blocker, has been developed in fixed-dose combinations (FDCs) with chlorthalidone (CTD).We compared FDCs of AZL-M/CTD 20/12.5 mg once daily titrated to 40/25 mg if needed or AZL-M/CTD 40/12.5 mg once daily titrated to 80/25 mg if needed (...) with an olmesartan medoxomil (OLM)-hydrochlorothiazide (HCTZ) 20/12.5 mg FDC once daily titrated to 40/25 mg if needed in a randomized, double-blind, 8-week study of 1085 participants with clinic SBP 160-190 mmHg and DBP 119 mmHg or less. Titration to higher doses occurred at week 4 if BP was at least 140/90 mmHg (≥130/80 mmHg if diabetes or chronic kidney disease). The primary endpoint was change from baseline in clinic SBP; 24-h ambulatory BP monitoring was also measured.Greater reductions in clinic SBP from

2018 Journal of Hypertension Controlled trial quality: uncertain PubMed abstract

17. Comparison of efficacy and safety between benidipine and hydrochlorothiazide in fosinopril-treated hypertensive patients with chronic kidney disease: protocol for a randomised controlled trial. (Full text)

Comparison of efficacy and safety between benidipine and hydrochlorothiazide in fosinopril-treated hypertensive patients with chronic kidney disease: protocol for a randomised controlled trial. Co-administration of a diuretic or calcium channel blocker with an ACE inhibitor are both preferred combinations in patients with hypertensive chronic kidney disease (CKD). According to the available evidence, it is still unknown which combination plays a more active role in renal protection. We (...) hypothesised that a combination of fosinopril and benidipine may delay the progression of CKD more effectively than a combination of fosinopril and hydrochlorothiazide (HCTZ).This study will be a multicentred, prospective, double-blind, randomised parallel controlled trial for hypertensive CKD patients in China. Patients will be randomised to one of two treatment groups: a combination of benidipine 4-8 mg/day and fosinopril 20 mg/day; or a combination of HCTZ 12.5-25 mg/day and fosinopril 20 mg/day

2017 BMJ open Controlled trial quality: predicted high PubMed abstract

18. Risk of hyponatremia with diuretics: chlorthalidone versus hydrochlorothiazide. (Abstract)

Risk of hyponatremia with diuretics: chlorthalidone versus hydrochlorothiazide. Chlorthalidone and hydrochlorothiazide are often considered as interchangeable. However, greater (nighttime) blood pressure reduction, and alleged pleiotropic effects have renewed the interest in chlorthalidone. A recent study showed an increased risk of adverse events with chlorthalidone, including hyponatremia.To investigate differences in risk of hyponatremia between chlorthalidone and hydrochlorothiazide (...) of onset.A total of 1033 cases of hyponatremia were identified. Hyponatremia was more common with chlorthalidone than with hydrochlorothiazide at equal dose per day: adjusted odds ratio was 2.09 (95% confidence interval [CI], 1.13-3.88) for 12.5 milligrams per day and 1.72 (95% CI, 1.15-2.57) for 25 milligrams per day. Risks were not significantly increased with chlorthalidone compared with twice the dose per day of hydrochlorothiazide.This is the first study that shows an increased risk of hyponatremia

2014 American Journal of Medicine

19. Clinical Inquiry: How do hydrochlorothiazide and chlorthalidone compare for treating hypertension? (Abstract)

Clinical Inquiry: How do hydrochlorothiazide and chlorthalidone compare for treating hypertension? 24905126 2014 07 30 2014 06 09 1533-7294 63 4 2014 Apr The Journal of family practice J Fam Pract Clinical inquiry: How do hydrochlorothiazide and chlorthalidone compare for treating hypertension? 227-8 Kildare Leanne L Valley Family Medicine, Renton, WA, USA. Jones Ty T Neher Jon O JO St Anna Leilani L eng Journal Article Review United States J Fam Pract 7502590 0094-3509 0 Antihypertensive (...) Agents 0J48LPH2TH Hydrochlorothiazide Q0MQD1073Q Chlorthalidone AIM IM Antihypertensive Agents adverse effects therapeutic use Chlorthalidone adverse effects therapeutic use Evidence-Based Medicine Humans Hydrochlorothiazide adverse effects therapeutic use Hypertension drug therapy 2014 6 7 6 0 2014 6 7 6 0 2014 7 31 6 0 ppublish 24905126 jfp_6304i

2014 Journal of Family Practice

20. Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden (Full text)

Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden Ekman M, Bienfait-Beuzon C, Jackson J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of irbesartan in combination with hydrochlorothiazide in comparison with other selective angiotensin-II-receptor blockers. The authors concluded that irbesartan combined with hydrochlorothiazide was a cost-effective alternative to valsartan and losartan

2008 NHS Economic Evaluation Database. PubMed abstract